5% more people given the PCSK9 inhibitor evolocumab (Repatha) to lower cholesterol levels died from cardiovascular causes during an average follow-up of 2.2 years than those given a placebo according to the FOURIER trial.

251 people (out of 13,784) given evolocumab died compared to 240 people (out of 13,780) given a placebo.

So they want me to take a drug that you have to inject that costs $14,000 per year that increases my chance of dying?

No, thank you.

Read the entire article | Email this article

Sedentary patients who were given a pedometer to wear increased the number of steps they took per day from an average of 6779 to 8855 in two months (nine weeks). Read the entire article | Email this article